ArticlePharmaceutical research2021
Performance of Area under the Concentration-Time Curve Estimations of Vancomycin with Limited Sampling by a Newly Developed Web Application.
Article in Pharmaceutical research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Efficacy and safety of vancomycin compared with those of alternative treatments for methicillin-resistant Staphylococcus aureus infections: An umbrella review.Journal of evidence-based medicine · 2024Pooled it
- Clinical practice guidelines for therapeutic drug monitoring of teicoplanin: a consensus review by the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring.The Journal of antimicrobial chemotherapy · 2022Guideline
- Practical dose ranges supporting target vancomycin exposure with AUC-guided dosing in overweight and obese patients: A multicentre retrospective study.British journal of clinical pharmacology · 2026Article
- Optimal vancomycin AUCEuropean journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Article
- Vancomycin Dosing Regimen to Obtain the Target Area Under the Concentration-Time Curve, Which Provides an Early Treatment Response for Patients on Haemodialysis.Antibiotics (Basel, Switzerland) · 2026Article
- Generating and Modeling Virtual Patient Data from Published Population Pharmacokinetic Analyses: A Vancomycin Case Study.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Use of nomograms based on the one-compartment model in the estimation of area under the blood concentration-time curve of vancomycin: a retrospective cohort study.European journal of clinical pharmacology · 2025Article
- Effect of discrepancy in estimated renal function on vancomycin area under the blood concentration-time curve: a retrospective cohort study comparing serum creatinine and serum cystatin C.International journal of clinical pharmacy · 2025Article
- Pharmacodynamics of Vancomycin Against Coagulase-Negative Staphylococci Bloodstream Infections.Pharmacology research & perspectives · 2025Review
- Impact of Sampling Strategy and Population Model on Bayesian Estimates of Vancomycin AUC in Patients with BMI > 40 kg/mMedicines (Basel, Switzerland) · 2025Article
- Risk Factors for Vancomycin-Induced Nephrotoxicity and Kidney Prognosis in Patients Aged 75 Years and Older: A Retrospective Study.Drugs & aging · 2025Article
- Shortening the interval between the first and the second dose of vancomycin facilitates rapid achievement of the target AUC without increasing the risk of acute kidney injury, provided the AUC on the second day is appropriately controlled: a multicenter retrospective study.Journal of pharmaceutical health care and sciences · 2025Article
- Antimicrobial therapy using vancomycin and therapeutic drug monitoring (TDM) in patient with bacteremia caused by Arthrobacter woluwensis:a case report.Journal of pharmaceutical health care and sciences · 2025Article
- Development and validation of a population pharmacokinetic model of vancomycin for patients of advanced age.Journal of pharmaceutical health care and sciences · 2025Article
- Factors affecting free vancomycin concentration and target attainment of free area under the concentration-time curve.Journal of pharmaceutical health care and sciences · 2025Article
- Identifying the Optimal Sampling Strategy for the Bayesian Estimation of Vancomycin AUCClinical pharmacokinetics · 2025Article
- PK/PD-Guided Strategies for Appropriate Antibiotic Use in the Era of Antimicrobial Resistance.Antibiotics (Basel, Switzerland) · 2025Review
- Interinstitutional Comparison of Vancomycin Area Under the Concentration-Time Curve Estimation in Korea: Need for Standardized Operational Protocols for Therapeutic Drug Monitoring Consultation.Annals of laboratory medicine · 2025Article
- Vancomycin levels for Bayesian dose-optimization in critical care: a prospective cohort study.Frontiers in medicine · 2025Article
- Identification of Patients Who Require Two-Point Blood Sampling for the Peak and Trough Values Rather Than One-Point Blood Sampling for the Trough Value for the Evaluation of AUC of Vancomycin Using Bayesian Estimation.Pharmaceutical research · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
purposeTherapeutic drug monitoring guided by the area under the concentration-time curve (AUC-guided TDM) is recommended for vancomycin. However, validated efficient software remains elusive to popularize AUC-guided TDM in Japan. The aim of this study was to validate a newly developed web application, PAT, for AUC estimation.
methodsPAT was developed on the R ver. 3.6.2 platform for use with mobile phones and personal computers. AUC estimated by PAT (AUC
resultsInvestigating the best sampling points with limited sampling, PAT produced the least bias using two concentrations at 1 h and 11 h after the end of infusion (slope 1.18, intercept -15.57, median AUC
conclusionsThe new application using two concentrations was appropriately validated and might be efficient in popularizing the AUC-guided TDM of vancomycin.
Indexed as
Identifiers
33782837What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.